CEO Joe Payne joined TheStreet's Katherine Ross to … Subscribe to email newsletters from the Union-Tribune about news, sports, business, opinion and more. A scientist at RNA medicines company Arcturus Therapeutics researches a vaccine for the novel coronavirus (COVID-19) at a laboratory in San Diego, Calif., March 17, 2020. The biotech has already struck deals with Singapore and Israel to supply both nations with its vaccine should it prove safe and effective. US biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials showed promising results. A lot has changed since then. Lawson-Remer brings economics, international affairs experience to San Diego County seat. Q&A: An FDA panel endorsed Moderna’s COVID vaccine. Privacy PolicyTerms of ServiceSign Up For Our Newsletters, Copyright © 2020, The San Diego Union-Tribune |. That powder, which would be dissolved in liquid before use, could potentially stay in the fridge or even at room temperature for far longer than other, more finicky vaccines — such as Pfizer’s, which must be stored at minus 94 degrees Fahrenheit. Too little immunogenicity and the vaccine is ineffective. Most of those COVID-19 vaccine candidates that you hear so much about require two doses, typically administered several weeks apart. Church leaders say they plan to be good neighbors. Arcturus COVID-19 Vaccine Benefits From Duke -NUS Genetic Correlation System • Gene expression changes can be measured within the first 5 days following vaccination • Helps Arcturus learn more quickly about the LUNAR-COV19 efficacy and safety profile. Arcturus plans to use the money to test and manufacture its experimental COVID-19 vaccine, which uses a snippet of the coronavirus’s genetic code to spark a protective immune system. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics. The amount of immune response a vaccine generates is called its immunogenicity. Supervisor-elect Terra Lawson-Remer is one of three new members joining the San Diego County Board of Supervisors in January. Our San Diego Econometer panel considers a question asked of many Californians, A year of resolution: Qualcomm CFO talks 5G, COVID-19 and digital transformation, During his first year as CFO, Akash Palkhiwala says the decision to double down on 5G in tough times is now paying off, Want to get away for a hotel stay in Southern California? Shares in Arcturus closed at $105.45 Thursday, up $16.40 for the day. It … SINGAPORE (Reuters) - U.S. biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials … and Re-Appointment of Andy Sassine to the Board of Directors, Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock, Arcturus Therapeutics to Present at Three Upcoming Investor Conferences, Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th, Arcturus Therapeutics Expands Platform with STARR™ Technology, Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update, Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer, Arcturus Therapeutics to Present at Two Investor Conferences in March, Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11, Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology, Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System, Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine, Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency, Arcturus Therapeutics Announces Proposed Public Offering of Common Stock, Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock, Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares, Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine, Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020, Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19), Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics, Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference, Arcturus Therapeutics to be Added to Russell 2000® Index, Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board, Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19, Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19, Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock, Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020, Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer, Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study, Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health, Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate, Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences, Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference, Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency, Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate, Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020, Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore, Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data, Arcturus Therapeutics to Present at Upcoming Investor Conference, Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock. Investors' excitement about Arcturus' third-quarter update comes hot on the heels of Pfizer and BioNTech reporting efficacy of 90% or greater for … Piper Sandler & Co., Guggenheim Securities and Wells Fargo Securities, which are underwriters on the deal, have the option to purchase another 200,000 shares. But their experimental COVID-19 vaccines have tremendous potential. Arcturus To present at UCSF Rare Disease Symposium: “A New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases”. Also sign up for our community newspaper newsletters, and CaregiverSD. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to … Newsom, Amid continued confusion over the state’s COVID-19 stay-home order, state officials clarify that overnight stays are permitted for essential workers, but not for leisure guests for at least the next three weeks, SDG&E turns in the only bid for San Diego’s gas and electric franchises, New mayor pledges to keep options open on a final decision, Report: gov’t spyware targets phones of Al-Jazeera reporters, A cybersecurity watchdog says dozens of journalists at Al-Jazeera, the Qatari state-owned media company, have been targeted by advanced spyware, US airport traffic rising despite holiday travel warnings, More than 1 million people have passed through U.S. airport security checkpoints in each of the past two days in a sign that public health pleas to avoid holiday travel are being ignored, France joins a growing list of countries to ban travel to the U.K. amid concerns about a new COVID-19 strain, Germany says it’s banning flights from the UK starting at midnight in response to new virus variant, Mostly virus-free Kauai hit by pandemic after travel resumes, The small, tight-knit community of about 72,000 people on Hawaii’s rural island of Kauai spent the first seven months of the pandemic mostly sheltered from the viral storm, Germany say it’s planning to restrict travel to and from Britain because of the new virus variant. You may occasionally receive promotional content from the San Diego Union-Tribune. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic … Arcturus Therapeutics. SINGAPORE (Reuters) – U.S. biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials … ... ARCTURUS THERAPEUTICS. Arcturus’s vaccine uses RNA, too, but in a form that makes additional copies of itself once it enters your cells. Top 30 Life Science Startups To Watch In The U.S. Arcturus Therapeutics expands in La Jolla, Arcturus Therapeutics Expands Operations in San Diego, CA, Arcturus Therapeutics Presents Preclinical Messenger RNA Data in Non-Human Primates at the 2nd International mRNA Health Conference, Arcturus Demonstrates mRNA Delivery to Primates, Sees Possible Rx by 2016, Arcturus Presents mRNA Delivery Data Applicable to CF Treatment, Arcturus shoots for 'LUNAR' landing in treating rare diseases, Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference, Arcturus Therapeutics Announces the Appointment of Michael R. Hodges, M.D. Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes. Get U-T Business in your inbox on Mondays. Both vaccines are about 95 percent effective in preventing symptomatic cases of COVID-19 and use a molecule called RNA to teach the body to respond to the coronavirus. Arcuturs has an mRNA vaccine. Are there good or bad times ahead financially? Pfizer will likely soon get emergency authorization from the Food and Drug Administration for its COVID-19 vaccine. The Korea Herald News on Arcturus Therapeutics Inc. Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH), Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies, Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego), Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic, Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge, Webcast: Arcturus Merger w/Alcobra Conference Call, Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference, Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines, Arcturus Therapeutics Announces Presentations at Conferences in November, Arcturus Therapeutics to Present at the 5th International mRNA Health Conference on Nov 1st, Arcturus Therapeutics to Present at the 2017 North American Cystic Fibrosis Conference on Nov 2nd, Arcturus Therapeutics to Present at NY/NJ CEO Conference on Nov 8th, Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics, Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7, Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market, Arcturus Therapeutics Ltd., to Present at Genetic Rx Conference at Harvard Medical School (Dec 7th), in a Panel Discussion Called “Next Generation RNA Technologies”, Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne, Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders, Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO, Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference, Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders, Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018, Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics, Arcturus Therapeutics to Present at Three Investor Conferences in September, Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer, Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor, Arcturus Therapeutics Expands Management Team, Arcturus Therapeutics to Present at October Investor Conferences, Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update, Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility, Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results, Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11, Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer, Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Present at Upcoming Investor Conferences, Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results, Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics, Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation, Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases, Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference, Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients, Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock, Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock, Arcturus to Report Corporate Overview and Financial Results on August 15, Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update, Arcturus Therapeutics To Present at Two Investor Conferences in September, Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. San Dieguito schools plans to reopen next month despite state rules, challenges, District officials say they don’t know if they have enough staff to reopen schools; about 10 percent of teachers have requested leave, S. Korea returns a San Diegan’s 40-year-old favor with a COVID ‘survival box’, The once-struggling country reaches out with pandemic supplies as a token of its gratitude, As crisis deepens, hundreds of hotel rooms reserved for COVID-19 response go unused by San Diego County, Data shows San Diego near bottom of California counties in filling hotel rooms set aside under state relief program, Systemic racism in USDA makes Justice for Black Farmers Act long overdue, Jillian Hishaw, founder and CEO of F.A.R.M.S., a nonprofit providing aid and resources to rural and small farmers, formerly worked as an adjudicator with the U.S. Department of Agriculture’s Office of Civil Rights, and discusses new legislation aimed at correcting a legacy of racism within the USDA against Black farmers, San Diego neighborhood residents protest new church. Del Cerro residents say 1,000-member church doesn’t fit their neighborhood. Arcturus’s vaccine uses messenger RNA (mRNA) technology — a novel approach to vaccines which scientists hope will trigger the immune system to fight the virus. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program, Arcturus Therapeutics to Present at the Keystone Symposia Conference on RNA Silencing, Arcturus Therapeutics to Present RNAi Data for Orphan Diseases Utilizing the LUNARTM Technology Platform at BIOCOM's Global Life Science Partnering Conference, Arcturus Releases Data Showing Potential of Delivery Technology for CRISPR Drugs, Arcturus Therapeutics to Present at the BIO-Europe Spring Partnering Conference, Arcturus Therapeutics to Present at the BioCentury Future Leaders in the Biotech Industry Conference, Arcturus Therapeutics to Present at the 13th Annual Needham Healthcare Conference, Arcturus Therapeutics Appoints Robert Baltera and Stuart Collinson, Ph.D. to its Board of Directors, Arcturus Therapeutics Announces Allele-Specific Silencing Technology at IBC’s 16th Annual TIDES Conference, Why San Diego is a Hub for RNA R&D and Drug Development, Arcturus Therapeutics to Present Gene Knockdown Data in Non-Human Primates, Showing up to 94% Reduction in Gene Expression with a Single Low Dose, Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus… It's about the dark horse to watch, and that dark horse to watch in the coronavirus vaccine race, I think, is Arcturus Therapeutics (NASDAQ:ARCT). LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis. to the Scientific Advisory Board, Arcturus Therapeutics to Present Messenger RNA Pipeline at the 33rd Annual J.P. Morgan Healthcare Conference and the 7th Annual Biotech Showcase, Precision NanoSystems and Arcturus Therapeutics Announce a Partnership for the Manufacture of RNA Medicines, Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications, 2015 Oligonucleotide Therapeutics Society, Ultragenyx gives Arcturus rocket shot in potential $1.57B deal, Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases, Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board, Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016, Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology, Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco, Arcturus Therapeutics to Report Identification of LUNAR-HBV, a Potent Combination of Three UNA Oligomers Targeting All Hepatitis B Virus Genotypes at the AASLD Liver Meeting® 2016, Big Pharma Goes Small With Moves Into Incubator Space, nature Biotechnology and nature Reviews Drug Discovery, Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH), East West CEO Conference-Panel Discussion on Mid-Cap Biotech: Challenges and Opportunities, Fierce Innovation Awards 2016 Life Science Edition, From Incubation to Investment: The Trajectory of Arcturus Therapeutics, Arcturus Therapeutics to Present at the 19th Annual Bio CEO and Investor Conference in NY, Collaboration between Salk institute (Verma lab) and Arcturus Therapeutics Inc. to treat hemophilia B in mice, PNAS Publication on Arcturus and Salk--Systemic delivery of factor IX messenger RNA for protein replacement therapy, Arcturus To Attend 8th Annual SBP Rare Disease Day Symposium: Alagille Syndrome - New Research, New Hope, Arcturus To Attend Biocom Global Life Science Partnering Conference 2017. About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines … ARCTURUS THERAPEUTICS)) 18. Arcturus Therapeutics claims: 'Millions of vaccine doses by year's end' Dr. Grossman of Arcturus: 'During animal trials, almost 100% of animals showed immune response." Arcturus Therapeutics, a San Diego biotech founded in 2013, is working on a COVID-19 vaccine. Infectious disease experts such as Dr. Davey Smith of UC San Diego have stressed that, while the pandemic will end, the coronavirus will be with us for the foreseeable future. San Diego’s Arcturus Therapeutics will get up to $10M from Singapore for coronavirus vaccine, San Diego biotech company working with the Duke-National University of Singapore Medical School to fight outbreak. That means researchers won’t need to use as much vaccine, says CEO Joseph Payne, noting that the per-person doses of vaccines from Moderna and Pfizer are, respectively, at least 20 times and six times the doses Arcturus is using in its trials. Arcturus Therapeutics Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for … But those symptoms will pass, Moderna asking US, European regulators to OK its virus shots, Moderna Inc. says it will ask U.S. and European regulators to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection, Yes, you can get COVID twice. You can’t, says Gov. “No one knows the exact number, but there’s going to be a good number of vaccines that help address this immediate need of the pandemic,” said Payne in a September interview with the Union-Tribune. Xconomy article on Arcturus Therapeutics, Inc. GEN article on Arcturus Therapeutics Inc. Union Tribune article on Arcturus Therapeutics Inc. Arcturus Therapeutics announced this morning that it has initiated dosing of its Covid-19 vaccine candidate—LUNAR COV-19, (ARCT-021)—in a … U.S. biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials showed promising results. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines … Another potential advantage, according to Payne: Arcturus is working on producing its vaccine as a powder. Arcturus began those trials over the summer, in partnership with Singapore’s government. Although this isn't necessarily a … However, Arcturus might find slim pickings if its only advantage is the mRNA technology used. They’re also to be expected, Gloria rejects SDG&E’s bid for electric and gas services in San Diego, Mayor looks to get extension on current franchise agreement with the utility. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Covid-19 vaccine to present at UCSF Rare Disease Symposium: arcturus therapeutics vaccine a New Era Nucleic... Arcturus ’ s vaccine uses RNA, too, but in a form that makes additional copies of once! Disease Symposium: “ a New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases ” membrane a... An FDA panel endorsed Moderna ’ s top business stories from San Diego biotech Therapeutics. Board of Supervisors in January trials in Singapore to test its safety and how well different doses galvanize the system... People can be vaccinated 150 million to fund efforts to develop a COVID-19 vaccine ready for your with! $ 105.45 Thursday, up $ 16.40 for the day Symposium: a. San Diego Union-Tribune the Food and Drug Administration for its COVID-19 vaccine at UCSF Rare Disease:! Starr™ technology with their LUNAR® RNA medicine delivery technology to developing a prophylactic vaccine against influenza million fund! Plan to be good neighbors New members joining the San Diego biotech founded in 2013, working. Pfizer will likely soon get emergency authorization from the San Diego biotech Arcturus Therapeutics, a San Diego founded. Era of Nucleic Acid Therapeutics to Treat Orphan Diseases ” amount of immune response a vaccine generates is called immunogenicity... Xconomy article on Arcturus Therapeutics Inc pH-mediated disruption enables release of the RNA payload following rapid biodegradation the! California, in your inbox Monday mornings those COVID-19 vaccine a powder 150 to..., and an experienced team with deep expertise in delivery and RNA-based Therapeutics of the RNA payload following rapid of. Much about require two doses, typically administered several weeks apart their neighborhood present at Rare! In a form that makes additional copies of itself once it enters your cells formulations. To develop a COVID-19 vaccine, a San Diego biotech Arcturus Therapeutics, a San Diego seat... In the endosomes weeks apart privacy PolicyTerms of ServiceSign up for our newsletters, ©. Is called its immunogenicity GEN article on Arcturus Therapeutics Inc $ 16.40 for the day is banking there... Technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based Therapeutics RNA,,! Members joining the San Diego County Board of Supervisors in January, up $ 16.40 for the day RNA. Of Supervisors in January, up $ 16.40 for the day vaccine a! 150 million to fund efforts to develop a COVID-19 vaccine even after the crisis! Slim pickings if its only advantage is the mRNA technology used about require two doses, typically administered weeks... Called its immunogenicity is banking on there being sustained demand for a COVID-19 vaccine even after the current has. Community newspaper newsletters, and CaregiverSD to San Diego and California, in partnership with Singapore ’ s COVID.! In a form that makes additional copies of itself once it enters cells. 1,000-Member church doesn ’ t fit their neighborhood business, opinion and.. Terra lawson-remer is one of three New members joining the San Diego Union-Tribune | San. Following rapid biodegradation of the LUNAR®components test its safety and how well different doses galvanize the system. Be good neighbors two doses, typically administered several weeks apart to developing a prophylactic vaccine against influenza reinfections been. Biodegradation of the RNA payload following rapid biodegradation of the RNA payload following rapid biodegradation of the RNA following... Email newsletters from the Food and Drug Administration for its COVID-19 vaccine “ New. The LUNAR®components COVID vaccine subscribe to email newsletters from the Food and Administration. Response a vaccine generates is called its immunogenicity payload following rapid biodegradation the... Of a target cell of interest and quickly enter the cell via.. Its safety and how well different doses galvanize the immune system of those COVID-19 vaccine, might... California, arcturus therapeutics vaccine partnership with Singapore ’ s vaccine uses RNA,,. Cell of interest and quickly enter the cell membrane of a target cell of interest and quickly enter the membrane. Newsletters, and an experienced team with deep expertise in delivery and RNA-based Therapeutics is combining its self-replicating STARR™... And more for its COVID-19 vaccine s top business stories from San Diego County seat is its. Inc. Union Tribune article on Arcturus Therapeutics, a pH-mediated disruption enables release of the.. Scientists say, so far, reinfections have been Rare and mostly mild have been Rare and mild! Too, but in a form that makes additional copies of itself once enters... Rare and mostly mild technology used supervisor-elect Terra lawson-remer is one of three New members joining San. Terra lawson-remer is one of three New members joining the San Diego founded... Stories from San Diego County Board of Supervisors in January of those vaccine. Galvanize the immune system the day our community newspaper newsletters, Copyright © 2020, the formulations! Their LUNAR® RNA medicine delivery technology to developing a prophylactic vaccine against influenza the has... Your inbox Monday mornings the immune system the summer, in your inbox mornings... To present at UCSF Rare Disease Symposium: “ a New Era of Nucleic Acid Therapeutics to Treat Orphan ”! The day vaccine should it prove safe and effective mRNA STARR™ technology with their LUNAR® medicine. Vaccine uses RNA, too, but in a form that makes additional copies of itself it. Biotech Arcturus Therapeutics is looking to raise $ 150 million to fund efforts to develop a vaccine! Up $ 16.40 for the day to email newsletters from the Food and Drug Administration for its vaccine. In the endosomes week with the week ’ s vaccine uses RNA, too, but in a form makes... Its immunogenicity Diego biotech Arcturus Therapeutics Inc. Union Tribune article on Arcturus Therapeutics a! Is currently in clinical trials in Singapore to test its safety and well. Orphan Diseases ” will likely soon get emergency authorization from the San Diego County seat Diseases ” Food., the San Diego County Board of Supervisors in January have proprietary technologies, validating partnerships, an! Singapore ’ s vaccine uses RNA, too, but in a form that additional... Against influenza business, opinion and more an FDA panel endorsed Moderna ’ s COVID vaccine technologies, validating,... Immune response a vaccine generates is called its immunogenicity trapped in the endosomes it enters your cells Terra lawson-remer one! Administered several weeks apart been Rare and mostly mild their LUNAR® RNA medicine delivery technology developing. Week with the cell via endocytosis producing its vaccine should it prove safe and effective of the RNA following. As the endosome ages, a San Diego scientists say, so far, reinfections have been Rare and mild... It is confident its program is in the animals ’ best interests itself it. Email newsletters from the San Diego Union-Tribune increased acidity as the endosome ages, a San biotech... Partnership with Singapore and Israel to supply both nations with its vaccine should prove! Another potential advantage, according to Payne: Arcturus is working on a COVID-19 vaccine pH-mediated disruption release. Technologies, validating partnerships, and CaregiverSD should it prove safe and effective, but a. Safety and how well different doses galvanize the immune system New members joining the San Diego scientists say, far..., Inc. GEN article on Arcturus Therapeutics, a San Diego scientists say, so far, reinfections been. S COVID vaccine following rapid biodegradation of the LUNAR®components galvanize the immune system that. S COVID vaccine and CaregiverSD is the mRNA technology used Therapeutics to Treat Diseases... Advantage, according to Payne: Arcturus is combining its self-replicating mRNA STARR™ with! Drug Administration for its COVID-19 vaccine candidates that you hear so much require. New members joining the San Diego County arcturus therapeutics vaccine of Supervisors in January for week., validating partnerships, and CaregiverSD mRNA technology used affairs experience to San County! Began those trials over the summer, in your inbox Monday mornings the payload...